Publications

FLAG continues to regularly publish in peer-reviewed scientific journals. Below is a list of our foundational publications that provide insights into the development of our two novel platforms, the Anti-angiogenic and Anti-tubulin (AA/AT) and Purine Synthesis Inhibitors (PSI).


AG488 as a therapy against gliomas

J Ziegler, A Bastian, M Lerner, L Bailey-Downs, Aleem Gangjee… - Oncotarget, 2017 - ncbi.nlm.nih.gov

High-grade gliomas such as glioblastomas (GBM) present a deadly prognosis following diagnosis and very few effective treatment options. Here, we investigate if the small molecule AG488 can be an effective therapy against GBM with both anti-angiogenic as well …

 

The design and discovery of water soluble 4-substituted-2, 6-dimethylfuro[2,3-d]pyrimidines as multitargeted receptor tyrosine kinase inhibitors and microtubule …

X Zhang, S Raghavan, M Ihnat, JE Thorpe, Aleem Gangjee… - Bioorganic & medicinal …, 2014 - Elsevier

The design, synthesis and biological evaluations of fourteen 4-substituted 2, 6-dimethylfuro [2, 3-d] pyrimidines are reported. Four compounds (11–13, 15) inhibit vascular endothelial growth factor receptor-2 (VEGFR-2), platelet-derived growth factor receptor β (PDGFR-β), and target tubulin leading to cytotoxicity. Compound 11 has nanomolar potency…



The promise and challenges of exploiting the proton-coupled folate transporter for selective therapeutic targeting of cancer

LH Matherly, Z Hou, A Gangjee - Cancer chemotherapy and …, 2018 - Springer

This review considers the “promise” of exploiting the proton-coupled folate transporter (PCFT) for selective therapeutic targeting of cancer. PCFT was discovered in 2006 and was identified as the principal folate transporter involved in the intestinal absorption of dietary folates. The recognition that PCFT was highly expressed in many tumors stimulated …



A new anti-glioma therapy, AG119: pre-clinical assessment in a mouse GL261 glioma model

RA Towner, M Ihnat, D Saunders, Aleem Gangjee… - BMC …, 2015 - bmccancer.biomedcentral.com

High grade gliomas (HGGs; grades III and IV) are the most common primary brain tumors in adults, and their malignant nature ranks them fourth in incidence of cancer death. Standard treatment for glioblastomas (GBM), involving surgical resection followed by radiation and chemotherapy with temozolomide (TMZ) and the anti-angiogenic therapy bevacizumab, have not substantially…